Helix cancer, infectious news
Helix said it has settled a proxy contest with a group of shareholders led by minority shareholder Andreas Kandziora and Zbigniew Lobacz. Under the settlement, Kenneth Cawkell, John Docherty, Lickrish, Kazimierz Roszkowski-Sliz and Donald Segal resigned as directors. Cawkell will remain as corporate secretary; Docherty will remain as president and COO; and Segal will remain as CEO for a transition period of up to six months, at which point he will resign. Mario Gobbo, Marek Orlowski and Robert Verhagen became directors. W. Thomas Hodgson will remain a director and former Chairman Jack Kay became a director. William White, the former chairman and interim CEO of Valeant Pharmaceuticals Inc., became chairman.
The group of dissident shareholders claimed the company and the company's product development were being mismanaged. Lobacz owns approximately 10% of the company's outstanding shares. ...